Source comparison
CJC-1295 no DAC vs CJC-1295 with DAC: The Half-Life Trade-Off
The DAC modification—attaching lysine chains to CJC-1295's structure—serves one purpose: extending plasma half-life from 30 minutes to approximately 6–8 days by binding to serum albumin. This creates a reservoir effect where peptide slowly dissociates from alb
This comparison does not assign a generated winner or score.
- The DAC modification—attaching lysine chains to CJC-1295's structure—serves one purpose: extending plasma half-life from 30 minutes to approximately 6–8 days by binding to serum albumin. This creates a reservoir effect where peptide slowly dissociates from albumin, maintaining stable plasma concentrations across days rather than hours. For researchers prioritising convenience, once-weekly dosing with DAC formulations eliminates the need for multiple daily injections.
- The downside is physiological. Natural GH secretion follows an ultradian rhythm—pulsatile release every 3–5 hours with peaks during deep sleep and post-exercise recovery. Sustained GHRH receptor activation from DAC formulations disrupts this pattern, creating constant low-level stimulation rather than mimicking endogenous pulses. Over weeks to months, this can lead to receptor downregulation—a compensatory mechanism where cells reduce receptor density in response to chronic signalling.
- CJC-1295 no DAC preserves pulsatility. Its 30-minute half-life means receptor occupancy peaks within 15–20 minutes post-administration and returns to baseline within 90–120 minutes. When dosed 2–3 times daily—typically upon waking, post-workout, and before sleep—it mimics the body's natural GH pulse frequency without sustained receptor saturation. Research protocols evaluating long-term efficacy consistently favour no-DAC formulations for this reason: maintained receptor sensitivity over 12+ week study periods.
- Our team sources exclusively no-DAC formulations in blended products. The convenience of weekly dosing doesn't offset the risk of diminished response curves across extended protocols—researchers running multi-month studies need consistent dose-response relationships, and DAC formulations compromise that reliability.